Takeda To Develop, Market Novartis Hib Drug In Japan
This article was originally published in PharmAsia News
Takeda Pharmaceuticals and Novartis have signed a partnership agreement to develop and market a vaccine to prevent meningitis in Japanese children. The vaccine is Novartis' Vaxem-Hib that prevents haemophilus influenza Type B, the lead cause of meningitis and pneumonia. Takeda is to conduct clinical trials in Japan for the vaccine and take the drug through the approval process, marketing it under the Novartis brand name. Takeda is paying Novartis just over $1 million initially, with milestone payments and royalties to follow. (Click here for more
You may also be interested in...
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.
How UK and EU device regulations will differ in 2021, UK approved bodies and Northern Ireland's unfettered access to the UK market were key themes at the ABHI’s annual regulatory conference.